DK1623019T4 - Begrænset glucosetilførsel til dyrecellekultur - Google Patents
Begrænset glucosetilførsel til dyrecellekultur Download PDFInfo
- Publication number
- DK1623019T4 DK1623019T4 DK04752591.0T DK04752591T DK1623019T4 DK 1623019 T4 DK1623019 T4 DK 1623019T4 DK 04752591 T DK04752591 T DK 04752591T DK 1623019 T4 DK1623019 T4 DK 1623019T4
- Authority
- DK
- Denmark
- Prior art keywords
- glucose
- cell culture
- rate
- culture
- cell
- Prior art date
Links
- 239000008103 glucose Substances 0.000 title claims abstract description 339
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 329
- 238000004113 cell culture Methods 0.000 title claims abstract description 108
- 210000004102 animal cell Anatomy 0.000 title claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 claims abstract description 67
- 238000000034 method Methods 0.000 claims abstract description 56
- 238000005070 sampling Methods 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims description 123
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 38
- 238000012384 transportation and delivery Methods 0.000 claims description 36
- 239000004310 lactic acid Substances 0.000 claims description 19
- 235000014655 lactic acid Nutrition 0.000 claims description 19
- 230000004044 response Effects 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 11
- 238000002156 mixing Methods 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract description 60
- 230000014616 translation Effects 0.000 abstract description 15
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 13
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 13
- 238000010923 batch production Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 description 44
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 30
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 30
- 210000004748 cultured cell Anatomy 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000007792 addition Methods 0.000 description 14
- 239000012526 feed medium Substances 0.000 description 14
- 239000012499 inoculation medium Substances 0.000 description 14
- 239000002609 medium Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 10
- 230000001276 controlling effect Effects 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000013459 approach Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 235000003642 hunger Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000006143 cell culture medium Substances 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 230000037351 starvation Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 241000255789 Bombyx mori Species 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012527 feed solution Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- RNVCVTLRINQCPJ-UHFFFAOYSA-N o-toluidine Chemical compound CC1=CC=CC=C1N RNVCVTLRINQCPJ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000001139 pH measurement Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 241000256118 Aedes aegypti Species 0.000 description 1
- 241000256173 Aedes albopictus Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108090000295 Nucellin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- -1 Trace D elements) Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007620 mathematical function Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Fodder In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (23)
1. Celledyrkningsfremgangsmåde til kontrol af mælkesyreproduktion til lave niveauer i en fed-batch-cellekultur omfattede: blanding af dyreceller og et medium for at danne en cellekultur; og tilføring af glucose på en begrænset vis til cellekulturen, hvor tilføring af glucose på en begrænset vis omfatter tilvejebringelse af glucose til cellekulturen ved en hastighed, som er en funktion af en forventet eller en præmodelleret glucoseforbrugshastighed af dyrecellerne dyrket i medium indeholdende et højt niveau af glucose, hvor funktionen er multiplikation af den forventede hastighed med en procentdel mindre end 100%, og hvor procentdelen er ikke mere end 45%, og hvor en pH-sensor anvendes til at monitorere cellekulturens pH, og i respons til en stigning over en forudbestemt pH-værdi, yderligere glucose tilføres på en begrænset vis til cellekulturen.
2. Fremgangsmåde ifølge krav 1, hvor procentdelen er mindst 33%.
3. Fremgangsmåde ifølge krav 1, hvor tilføring af glucose på en begrænset vis omfatter tilsætning af én eller flere bolusser af glucosetilførsel.
4. Fremgangsmåde ifølge krav 1, hvor tilføringen af glucose på en begrænset vis tilvejebringes uden feedback-kontrol-prøveudtagning i løbet af dyrkning.
5. Fremgangsmåde ifølge krav 1, hvor en sensor anvendes til at monitorere cellekoncentration i cellekulturen, og en cellekoncentrationssensor-afledt måling yderligere anvendes i beregning af hastigheden af tilføring af glucose på en begrænset vis til cellekulturen.
6. Fremgangsmåde ifølge krav 1, hvor den den yderligere glucose tilført på en begrænset vis omfatter én eller flere bolusser af glucosetilførsel.
7. Fremgangsmåde ifølge krav 1, hvor den forudbestemte pH-værdi er omtrent 7.
8. Fremgangsmåde ifølge krav 1, hvor en pH-sensor anvendes til at monito-rere cellekulturens pH, og i respons til en stigning over en forudbestemt pH-værdi, tilføring af glucose på en begrænset vis efterfølgende forsætter ved en ny hastighed, som er større end en umiddelbart foregående hastighed.
9. Fremgangsmåde ifølge krav 8, hvor den ny hastighed er større med mindst 15% over den umiddelbart foregående hastighed.
10. Fremgangsmåde ifølge krav 8, hvor den ny hastighed er større med ikke mere end 50% over den umiddelbart foregående hastighed.
11. Fremgangsmåde ifølge krav 8, hvor responset til en stigning over en forudbestemt pH-værdi yderligere omfatter tilsætning af én eller flere bolusser af glucosetilførsel til cellekulturen.
12. Fremgangsmåde ifølge krav 8, hvor den forudbestemte pH-værdi er omtrent 7.
13. Fremgangsmåde ifølge krav 1, hvor (i) en cellekoncentrationssensor anvendes til at monitorere cellekoncentration i cellekulturen uden prøveudtagning, og en cellekoncentrationssensor-afledt måling yderligere anvendes i beregning af hastigheden af tilføring af glucose på en begrænset vis til cellekulturen; (ii) en pH-sensor anvendes til at monitorere cellekulturens pH uden prøve-tagning, og i respons til en stigning over en forudbestemt pH-værdi, tilføring af glucose på en begrænset vis efterfølgende fortsætter ved en ny hastighed, som er større end en umiddelbart foregående hastighed; eller (iii) både cellekoncentrationssensoren og pH-sensoren anvendes som beskrevet i henholdsvis (i) og (ii).
14. Fremgangsmåde ifølge krav 13, hvor responset til en stigning over en forudbestemt pH-værdi i (ii) og/eller (iii) yderligere omfatter tilsætning af én eller flere bolusser af glucosetilførsel til cellekulturen.
15. Fremgangsmåde ifølge krav 13, hvor den forudbestemte pH-værdi er omtrent 7.
16. Fremgangsmåde ifølge krav 1, hvor den præmodellerede hastighed bestemmes ved blanding af dyreceller og et medium indeholdende et højt niveau af glucose for at danne en første cellekultur; og bestemmelse af en glu-coseforbrugshastighed for dyrecellerne dyrket i den første cellekultur.
17. Fremgangsmåde ifølge krav 16, hvor en pH-sensor anvendes til at moni-torere pH af den anden cellekultur, og i respons til en stigning over en forudbestemt pH-værdi, tilføring af glucose på en begrænset vis yderligere omfatter tilsætning af én eller flere bolusser af glucosetilførsel til den anden cellekultur.
18. Fremgangsmåde ifølge krav 17, hvor tilføring af glucose på en begrænset vis til den anden kultur yderligere omfatter efterfølgende fortsættelse af tilføring ved en ny hastighed, som er større end en umiddelbart foregående hastighed.
19. Fremgangsmåde ifølge krav 17, hvor den forudbestemte pFI-værdi er omtrent 7.
20. Fremgangsmåde ifølge krav 18, hvor den ny hastighed er større med mindst 15% over den umiddelbart foregående hastighed.
21. Fremgangsmåde ifølge krav 18, hvor den ny hastighed er større med ikke mere end 50% over den umiddelbart foregående hastighed.
22. Fremgangsmåde ifølge krav 1, hvor den præmodellerede hastighed bestemmes ved blanding af dyreceller og et medium indeholdende et højt niveau af glucose for at danne en første cellekultur; bestemmelse af en glucoseforbrugshastighed for dyrecellerne dyrket i den første cellekultur; blanding af dyreceller og et medium for at danne en anden cellekultur; og tilføring af glucose på en begrænset vis til den anden cellekultur ved en hastighed, som er en funktion af den bestemte glucoseforbrugshastighed; hvor (i) en cellekoncentrationssensor anvendes til at monitorere cellekoncentrationen i den anden cellekultur uden prøvetagning, og en cellekoncentrations-sensor-afledt måling yderligere anvendes i beregning af hastigheden af tilfø-ring af glucose på begrænset vis til den anden cellekultur; (ii) en pH-sensor anvendes til at monitorere pH af den anden cellekultur uden prøveudtagning, og i respons til en stigning over en forudbestemt pH-værdi, tilføring af glucose på en begrænset vis efterfølgende fortsætter ved en ny hastighed, som er større end en umiddelbart foregående hastighed; eller (iii) både cellekoncentrationssensoren og pH-sensoren anvendes som beskrevet i henholdsvis (i) og (ii).
23. Fremgangsmåde ifølge krav 22, hvor responset til en stigning over en forudbestemt pH-værdi i (ii) og/eller (iii) yderligere omfatter tilsætning af én eller flere bolusser af glucosetilførsel til den anden cellekultur.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47093703P | 2003-05-15 | 2003-05-15 | |
| PCT/US2004/015597 WO2004104186A1 (en) | 2003-05-15 | 2004-05-17 | Restricted glucose feed for animal cell culture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK1623019T3 DK1623019T3 (da) | 2010-09-27 |
| DK1623019T4 true DK1623019T4 (da) | 2017-03-27 |
Family
ID=33476770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04752591.0T DK1623019T4 (da) | 2003-05-15 | 2004-05-17 | Begrænset glucosetilførsel til dyrecellekultur |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7429491B2 (da) |
| EP (1) | EP1623019B2 (da) |
| AT (1) | ATE472597T2 (da) |
| DE (1) | DE602004027905D1 (da) |
| DK (1) | DK1623019T4 (da) |
| ES (1) | ES2344789T5 (da) |
| PL (1) | PL1623019T5 (da) |
| PT (1) | PT1623019E (da) |
| SI (1) | SI1623019T1 (da) |
| WO (1) | WO2004104186A1 (da) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ597334A (en) | 2006-09-13 | 2014-02-28 | Abbott Lab | Cell culture improvements |
| US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
| WO2008036600A2 (en) * | 2006-09-18 | 2008-03-27 | Genentech, Inc. | Methods of protein production |
| JP5564259B2 (ja) * | 2006-11-08 | 2014-07-30 | ワイス・エルエルシー | 細胞培養のための合理的に設計された培地 |
| WO2009023562A2 (en) | 2007-08-09 | 2009-02-19 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| WO2009129379A1 (en) * | 2008-04-17 | 2009-10-22 | Wyeth | Methods for enhanced production of bone morphogenetic proteins |
| US8318416B2 (en) * | 2008-08-08 | 2012-11-27 | Biogen Idec Ma Inc. | Nutrient monitoring and feedback control for increased bioproduct production |
| AU2009347206C1 (en) | 2008-10-20 | 2016-12-08 | Abbvie Inc. | Isolation and purification of antibodies using Protein A affinity chromatography |
| MX2011004201A (es) | 2008-10-20 | 2011-05-24 | Abbott Lab | Desactivacion viral durante purificacion de anticuerpos. |
| HUE067718T2 (hu) * | 2009-10-26 | 2024-11-28 | Hoffmann La Roche | Eljárás glikozilált immunglobulin elõállítására |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| CN105189735B (zh) | 2011-04-29 | 2019-04-12 | 拜康研究有限公司 | 在培养期间减少乳酸累积的方法和生产多肽的方法 |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| KR20150043523A (ko) | 2012-09-02 | 2015-04-22 | 애브비 인코포레이티드 | 단백질 불균일성의 제어 방법 |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| WO2014143205A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US8921526B2 (en) | 2013-03-14 | 2014-12-30 | Abbvie, Inc. | Mutated anti-TNFα antibodies and methods of their use |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| DK2972238T3 (da) | 2013-03-15 | 2023-06-19 | Biogen Ma Inc | Anvendelse af raman-spektroskopi til monitorering af dyrkningsmedium |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| WO2015000865A1 (en) | 2013-07-04 | 2015-01-08 | F. Hoffmann-La Roche Ag | Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| JP6663854B2 (ja) | 2013-10-11 | 2020-03-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 代謝が最適化された細胞培養 |
| US11390663B2 (en) | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP3119876B1 (en) | 2014-03-19 | 2024-12-18 | Pfizer Inc. | Method of cell culture |
| US10563163B2 (en) | 2014-07-02 | 2020-02-18 | Biogen Ma Inc. | Cross-scale modeling of bioreactor cultures using Raman spectroscopy |
| AU2016271607C1 (en) * | 2015-05-29 | 2023-06-29 | Boehringer Ingelheim International Gmbh | Cell-controlled perfusion in continuous culture |
| US20180291329A1 (en) * | 2015-05-29 | 2018-10-11 | Biogen Ma Inc. | Cell culture methods and systems |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| EP4446338A3 (en) | 2015-09-23 | 2025-05-07 | Pfizer Inc. | Cells and method of cell culture |
| US12503700B2 (en) | 2017-03-14 | 2025-12-23 | Amgen Inc. | Control of total afucosylated glycoforms of antibodies produced in cell culture |
| GB201708655D0 (en) | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| JP2021519068A (ja) | 2018-03-26 | 2021-08-10 | アムジェン インコーポレイテッド | 細胞培養において産生される抗体の総非フコシル化グリコフォーム |
| CN112218877B (zh) | 2018-08-27 | 2025-07-25 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| KR20210091763A (ko) | 2018-11-13 | 2021-07-22 | 얀센 바이오테크 인코포레이티드 | 항-cd38 항체의 생성 동안 미량 금속의 제어 |
| WO2020115655A1 (en) | 2018-12-06 | 2020-06-11 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
| CA3158201A1 (en) * | 2019-10-18 | 2021-04-22 | Janssen Biotech, Inc. | Dynamic monosaccharide control processes |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| JP7822149B2 (ja) | 2020-10-02 | 2026-03-02 | ファイザー・インク | Ｒｓｖ ｆタンパク質生産のための細胞培養工程 |
| US12031151B2 (en) | 2021-01-20 | 2024-07-09 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| CA3253362A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | PROCESS FOR MANUFACTURED HIGH-TITLE ANTIBODY |
| WO2023230209A1 (en) | 2022-05-25 | 2023-11-30 | Genentech, Inc. | Methods for preparing mammalian cells for perfusion cell culture |
| EP4698631A1 (en) | 2023-04-21 | 2026-02-25 | Pfizer Inc. | Improved cells and cell cultures |
| WO2025088516A1 (en) | 2023-10-26 | 2025-05-01 | Pfizer Inc. | Method of forming multi-specific antibodies from homodimer antibodies and pharmaceutical product including multi-specific antibodies thus obtained |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| US5631142A (en) | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
| US5346826A (en) * | 1989-10-18 | 1994-09-13 | Andrews Franklin T | Process for conducting biochemical reactions |
| US5506117A (en) * | 1989-10-18 | 1996-04-09 | Cytokinetics, Inc. | Biochemical process for growing living cells by measuring the amount of nutrient added to the reaction medium |
| US5318898A (en) | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
| US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| WO1998041611A1 (en) | 1997-03-20 | 1998-09-24 | Regents Of The University Of Minnesota | Process for the continuous culture of cells |
| US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| EP1404813A4 (en) * | 2001-06-13 | 2004-11-24 | Genentech Inc | METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS |
| DE10255508A1 (de) | 2002-11-27 | 2004-06-17 | Forschungszentrum Jülich GmbH | Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen |
-
2004
- 2004-05-17 PL PL04752591T patent/PL1623019T5/pl unknown
- 2004-05-17 AT AT04752591T patent/ATE472597T2/de active
- 2004-05-17 DK DK04752591.0T patent/DK1623019T4/da active
- 2004-05-17 WO PCT/US2004/015597 patent/WO2004104186A1/en not_active Ceased
- 2004-05-17 DE DE602004027905T patent/DE602004027905D1/de not_active Expired - Lifetime
- 2004-05-17 ES ES04752591.0T patent/ES2344789T5/es not_active Expired - Lifetime
- 2004-05-17 PT PT04752591T patent/PT1623019E/pt unknown
- 2004-05-17 EP EP04752591.0A patent/EP1623019B2/en not_active Expired - Lifetime
- 2004-05-17 SI SI200431499T patent/SI1623019T1/sl unknown
- 2004-05-17 US US10/847,729 patent/US7429491B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1623019B1 (en) | 2010-06-30 |
| US7429491B2 (en) | 2008-09-30 |
| DK1623019T3 (da) | 2010-09-27 |
| PL1623019T5 (pl) | 2018-02-28 |
| ATE472597T2 (de) | 2010-07-15 |
| ES2344789T5 (es) | 2017-06-14 |
| SI1623019T1 (sl) | 2010-10-29 |
| EP1623019A1 (en) | 2006-02-08 |
| ES2344789T3 (es) | 2010-09-07 |
| US20050070013A1 (en) | 2005-03-31 |
| WO2004104186A1 (en) | 2004-12-02 |
| DE602004027905D1 (de) | 2010-08-12 |
| PT1623019E (pt) | 2010-07-20 |
| PL1623019T3 (pl) | 2010-10-29 |
| EP1623019B2 (en) | 2017-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1623019T4 (da) | Begrænset glucosetilførsel til dyrecellekultur | |
| JP7700184B2 (ja) | 灌流バイオリアクタ及び関連する使用方法 | |
| US6156570A (en) | Process for the continuous culture of cells | |
| US4999298A (en) | Hollow fiber bioreactor culture system and method | |
| Fibach et al. | Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells | |
| RU2577972C2 (ru) | Способ получения рекомбинантного полипептида | |
| WO1998041611A9 (en) | Process for the continuous culture of cells | |
| JP6393267B2 (ja) | かん流細胞培養システムを最適化するための方法およびシステム | |
| Hu et al. | Monitoring and control of animal cell bioreactors: Biochemical engineering considerations | |
| US20200255785A1 (en) | Online biomass capacitance monitoring during large scale production of polypeptides of interest | |
| JP2018516079A (ja) | 連続培養における細胞コントロール灌流 | |
| KR20110093646A (ko) | 세포 생존률 및 생물학적 생성물 수율의 향상을 위한 포유동물 세포 배양 공정에서 ｐＨ, 삼투몰농도 및 용존 이산화탄소 수준의 조절 방법 | |
| Wang et al. | Measurements on the interfacial areas of hydrocarbon in yeast fermentations and relationships to specific growth rates | |
| JP2025134848A (ja) | 接種物を生産するためのプロセスおよびシステム | |
| CN121406558A (zh) | 浓缩灌注培养基 | |
| EP0567738A2 (en) | Controlling perfusion rates in continuous bioreactor culture of animal cells | |
| Han et al. | Cultivation of Dictyostelium discoideum on an improved synthetic medium in a conventional bioreactor | |
| Gambhir et al. | Analysis of the use of fortified medium in continuous culture of mammalian cells | |
| US20240182843A1 (en) | Variable-volume chemostat and applications thereof | |
| US20240083972A1 (en) | Cell culture method | |
| RU2088258C1 (ru) | Способ изготовления вакцины против лептоспироза животных | |
| Dubois et al. | High-Density Cytostat Cell Cultures with Homeostasis of Glucids and Amino Acids | |
| Fenge et al. | Perfusion bioreactor performance at different cell bleed rates | |
| KR100392411B1 (ko) | 주정폐액을이용한효모배양에있어서포도당과암묘늄의자동첨가에의한증균법 | |
| Tonso | Monitoring and control of cell cultures |